ReviewGeroScience2018
The potential of non-myeloablative heterochronous autologous hematopoietic stem cell transplantation for extending a healthy life span.
Review in GeroScience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Differential effects of young and old hematopoietic stem cell niches on bone marrow-derived dendritic cells.Immunity & ageing : I & A · 2025Article
- The Treatment of Refractory Vitiligo With Autologous Cultured Epithelium Grafting: A Real-World Retrospective Cohort Study.Stem cells translational medicine · 2024Article
- Application of exosomes in tumor immunity: recent progresses.Frontiers in cell and developmental biology · 2024Review
- Morphological Characteristics of Young and Old Murine Hematopoietic Stem Cell Niches, as ModeledScanning · 2023Article
- Genetic enhancement: an avenue to combat aging-related diseases.Life medicine · 2022Review
- The Influence of Heterochronic Non-Myeloablative Bone Marrow Transplantation on the Immune System, Frailty, General Health, and Longevity of Aged Murine Recipients.Biomolecules · 2022Article
- Article
- Caveolin-1 promotes radioresistance via IRGM-regulated autophagy in lung cancer.Annals of translational medicine · 2021Article
- Clinical implication of cellular vaccine in glioma: current advances and future prospects.Journal of experimental & clinical cancer research : CR · 2020Review
- Exosome-based immunotherapy: a promising approach for cancer treatment.Molecular cancer · 2020Review
- BRCA1-Associated Protein Is a Potential Prognostic Biomarker and Is Correlated With Immune Infiltration in Liver Hepatocellular Carcinoma: A Pan-Cancer Analysis.Frontiers in molecular biosciences · 2020Article
- Rheostatic Balance of Circadian Rhythm and Autophagy in Metabolism and Disease.Frontiers in cell and developmental biology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Aging is a complex multifactorial process, a prominent component being the senescence of the immune system. Consequently, immune-related diseases develop, including atherosclerosis, cancer, and life-threatening infections, which impact on health and longevity. Rejuvenating the aged immune system could mitigate these diseases, thereby contributing to longevity and health. Currently, an appealing option for rejuvenating the immune system is heterochronous autologous hematopoietic stem cell transplantation (haHSCT), where healthy autologous bone marrow/peripheral blood stem cells are collected during the youth of an individual, cryopreserved, and re-infused when he or she has reached an older age. After infusion, young hematopoietic stem cells can reconstitute the compromised immune system and improve immune function. Several studies using animal models have achieved substantial extension of the life span of animals treated with haHSCT. Therefore, haHSCT could be regarded as a potential procedure for preventing age-related immune defects and extending healthy longevity. In this review, the pros, cons, and future feasibility of this approach are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.